Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
BridgeBio Pharma, Inc. | Director | Common Stock | 917K | $44M | $48.00 | Aug 11, 2025 | Direct |
Maze Therapeutics, Inc. | Director | Common Stock | 58K | Feb 3, 2025 | Direct | ||
Maze Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 18K | Sep 22, 2025 | Direct | ||
PLIANT THERAPEUTICS, INC. | Director | Stock Option (right to buy) | 13.3K | Jun 29, 2021 | Direct | ||
BridgeBio Pharma, Inc. | Director | Stock Option (Right to Buy) | 8.43K | Jun 20, 2025 | Direct | ||
Maze Therapeutics, Inc. | Director | Common Stock | 7.42K | Feb 3, 2025 | By Trust | ||
Maze Therapeutics, Inc. | Director | Series D-1 Preferred Stock | 7.42K | Nov 26, 2024 | By Trust | ||
Maze Therapeutics, Inc. | Director | Series B Preferred Stock | 0 | Feb 3, 2025 | Direct | ||
Maze Therapeutics, Inc. | Director | Series C Preferred Stock | 0 | Feb 3, 2025 | Direct | ||
Maze Therapeutics, Inc. | Director | 8% Convertible Note due 2026 | $0 | Nov 26, 2024 | By Trust |